Facebook-f Instagram Twitter Linkedin-in
  • info@viridiontherapeutics.com
Viridion Therapeutics Logo
Contact
Investor Opportunity

Viridion is raising a $20M Series A to advance
CARG-2020 into Phase I/Ib.

First-in-Class

No approved therapy addresses all three TME suppression mechanisms in a single construct.

De-Risked Science

100% preclinical eradication rate; peer-reviewed in 3 journals; FDA Pre-IND complete.

Platform Value

Single product derived from AVIDIO™ platform supports multiple indications.

IP Protected

Composition-of-matter patent to 2044 — the strongest protection class in pharmaceuticals.

Experienced Team

From Yale University School of Medicine and major pharmaceutical and biotechnology companies.

Capital Efficient

One manufacturing process across all indications; intraperitoneal for Phase I/Ib ovarian cancer patients.

Contact: Dr. Bijan Almassian, CEO & Founder · balmassian@viridiontherapeutics.com · viridiontherapeutics.com

Investor Opportunity

Advance CARG-2020 into Human Phase I/Ib Trials.

Viridion Therapeutics is raising a $20M Series A to advance CARG-2020 — a first-in-class multifunctional immunotherapy — into Phase I/Ib clinical trials for recurrent ovarian cancer.

Yale-Origin Science
U.S. Patent Issued — Protected to 2044
4 Tumor Types Validated
Series A Raise
$ 0 M
Total Addressable Market
$ 0 B+
Return Potential
5- 0 x
The Problem

Tumors Shrink. But Patients Still Die.

60–80% of solid tumor patients experience recurrence within 3–5 years. Recurrence — not the initial tumor — is the primary driver of cancer mortality. No approved therapy addresses all three immune suppression mechanisms simultaneously.
Learn more
Immune Exhaustion

Tumors upregulate PD-L1, switching off T-cells that would otherwise attack residual disease.

Immune Exclusion

Suppressive signaling physically prevents T-cells from entering the tumor microenvironment — rendering even activated immune cells ineffective.

Tumor-Promoting Inflammation

The IL-17 pathway creates a chronic inflammatory shield that protects surviving cancer cells from immune attack.

No Existing Solution

Current immunotherapies target a single immune axis. Durable control requires addressing all three mechanisms simultaneously.

The Solution

CARG-2020: One Construct. Three Mechanisms.

Built on the AVIDIO™ self-amplifying VLV platform, CARG-2020 is the only therapy in development that simultaneously targets all three suppression mechanisms in a single localized treatment.
IL-12

Activates Immunity

Converts suppressed immunity to an active anti-tumor T-cell response
Learn more
IL-17

Blocks Inflammation

Removes the inflammatory shield protecting residual tumors from immune attack
Learn more
Doctors testing
PD-L1

Silences Checkpoints

Prevents tumors from hiding from the immune system via checkpoint escape
Learn more
Preclinical result:
100% tumor eradication + durable immune memory — CARG-2020 treated animals showed 0% tumor regrowth after rechallenge vs. 100% progression in controls. (Alvero et al., Cancer Immunol Res, 2023)
Market Opportunity

$9.7B Beachhead. $92B+ Platform.

CARG-2020 enters through recurrent ovarian cancer, then expands across tumor types — each new indication is an independent licensing opportunity on the same platform.
Lead Indication — Phase I/Ib

$9.7B

Recurrent Ovarian Cancer — ~22,000 U.S. diagnoses/year, 70% recurrence rate, limited approved treatment options

Preclinical Efficacy Shown

$11.9B

Melanoma Immunotherapy — Cross-tumor immune memory confirmed in preclinical models

Preclinical Efficacy Shown

$70.5B

Triple-Negative Breast Cancer — High unmet need, limited approved options, large addressable population

Total (3 Indications)

$92.1B

Platform expansion potential — each new indication is an independent licensing opportunity

Pipeline

AVIDIO™ Multi-Indication Platform

ProgramIndicationStage
CARG-2020Ovarian CancerIND-Enabling
CARG-2020Triple-Negative Breast CancerPreclinical
CARG-2020MelanomaPreclinical
Use of Funds

$20M — 3-Year Path to Proof-of-Concept

Year 1

~$4.8M

  • Manufacturing process development
  • Analytical & bioanalytical development
  • Preclinical animal studies

Manufacturing & safety established

Year 2

~$8.3M

  • GMP manufacturing & GLP toxicology
  • IND preparation & filing
  • Phase I/Ib site activation & enrollment

IND filed & accepted by FDA

Year 3

~$6.9M

  • Phase I/Ib dose escalation
  • Patient safety monitoring
  • Biomarker analysis

First safety + biomarker data

Value Inflection: First-in-Human Proof-of-Concept

First-in-human validation of a new class of multivalent replicating mRNA immunotherapy. Phase I positive data positions Viridion for:
  • Pharma licensing deal ($50–200M+)
  • Series B at a higher valuation
  • Strategic acquisition interest

5–15x

Return potential
$20M → $100–300M+ enterprise value
Intellectual Property

Protected to 2044 — De-Risked by Design

U.S. Patent No. 12,577,585

Composition-of-matter patent covering the VLV platform. Issued March 2026. 18+ years of exclusivity remaining. Additional filings in progress.

Clinically Validated Components

IL-12 (multiple Phase I/II trials), PD-L1 blockade (standard of care, $40B+ market), IL-17 modulation (approved in autoimmune disease).

Peer-Reviewed Science

Published in Cancer Immunol Res (2023), Acta Pharmaceutica Sinica B (2024), and Scientific Reports (2025). Originated from Yale School of Medicine.

Regulatory Position

Potential eligibility for Orphan Drug and Breakthrough Therapy designations for recurrent ovarian cancer.

Ready to Learn More?

Request the full investor deck or schedule a conversation with our leadership team.

Request Investor Materials
Direct inquiries: balmassian@viridiontherapeutics.com Dr. Bijan Almassian, CEO & Founder